SuperSelective Primer Assay for Multidrug-Resistant TB Detection

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current TB diagnostic methods are insensitive in detecting low levels of mutant Mycobacterium tuberculosis, particularly in a wild-type background, limiting the detection of heteroresistance and multidrug-resistant TB.

Innovation Solution

The development of SuperSelective primers for real-time PCR assays, which enable selective and exponential amplification of specific point mutations in the presence of abundant wild-type DNA, specifically targeting the katG, inhA promoter, and rpoB genes associated with drug resistance.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If standard PCR methods are used, then the assay can detect mutant M. tuberculosis, but the detection sensitivity is insufficient when mutant DNA is present at low levels (1-10% limit of quantification) in a wild-type background

Engineering Contradiction:
Improvedetection sensitivityVSAvoidassay complexity
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The primer is divided into three functional segments: an anchor sequence (10-50 nucleotides) that binds to conserved regions, a bridge sequence (5-20 nucleotides) that creates a single-stranded bubble, and a foot sequence (5-20 nucleotides) that provides mutation-specific binding. This segmentation allows each region to perform its specialized function, achieving ultra-sensitive detection without requiring complex multi-component systems.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

Different regions of the primer are赋予 different binding characteristics: the anchor sequence has high stability for robust binding, the bridge sequence has no complementarity to create selective mismatch, and the foot sequence has perfect complementarity to the mutant target. This local differentiation of binding properties enables the primer to selectively amplify mutant DNA while ignoring wild-type DNA, achieving 0.01% detection sensitivity.

Inventive Principle:
Principle #3Local quality

2Reliability

If conventional primers are used, then the assay can amplify target DNA, but the primers cannot selectively amplify mutant sequences in the presence of abundant wild-type DNA

Engineering Contradiction:
ImprovespecificityVSAvoidprimer design complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The primer design introduces asymmetry in the bubble region, where the bridge sequence length (5-20 nucleotides) and intervening sequence length (5-20 nucleotides) can be optimized independently. This asymmetric design allows the single-stranded bubble to effectively separate the anchor and foot sequences, enabling the foot sequence to selectively bind to the mutant target while the anchor provides stable binding, achieving high specificity without symmetric complexity.

Inventive Principle:
Principle #4Asymmetry

Solution Approach 2:

The bridge sequence is pre-designed to be non-complementary to the target sequence, creating a predetermined single-stranded bubble structure before hybridization occurs. This preliminary structural arrangement ensures that during annealing, the foot sequence can exclusively bind to the mutant target sequence with perfect complementarity, while the wild-type sequence with its mismatch cannot form a stable hybrid,从而实现高特异性扩增.

Inventive Principle:
Principle #10Preliminary action

3Reliability

If the foot sequence is made longer to improve mutation discrimination, then the specificity increases, but the risk of non-specific binding to wild-type DNA increases

Engineering Contradiction:
Improvemutation discriminationVSAvoidnon-specific binding
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The foot sequence is designed with partial complementarity to the mutant target (perfect match) and intentional mismatch to the wild-type target. By optimizing the foot sequence length to 5-20 nucleotides, the design achieves sufficient discrimination power without excessive length that would increase non-specific binding risk. The mismatch position is strategically placed to maximize discrimination while minimizing off-target effects.

Inventive Principle:
Principle #16Partial or excessive action

Solution Approach 2:

The bridge sequence acts as an intermediary element that physically separates the anchor sequence from the foot sequence through the single-stranded bubble structure. This intermediary arrangement allows the foot sequence to exert its mutation-discrimination function independently without being constrained by the anchor sequence, enabling optimal foot sequence length and mismatch positioning that maximize specificity while minimizing non-specific binding.

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The SuperSelective primer-based assays achieve a detection limit of 0.01% for mutant DNA in a wild-type background, significantly improving the sensitivity for detecting heteroresistant and multidrug-resistant TB strains.

Implementation Method 1

The SuperSelective primer comprises one or more target-complementary sequences that are at least 85% identical to one selected from those listed in Table 2 below or the group consisting of SEQ ID NOs: 7-78

Methodology Applied
Scientific EffectNucleic acid hybridization:

Implementation Method 2

amplifying the first target segment in the reaction mixture with the first primer pair to generate a first amplicon

Methodology Applied
Scientific EffectPCR amplification:

Data Source

PatentUS20250034659A1Detection of multidrug-resistant mycobacterium tuberculosis using superselective primer-based real-time PCR assays
Publication Date: 2025.01.30 RUTGERS THE STATE UNIV
  • US20250034659A1 patent drawing
  • US20250034659A1 patent drawing
  • US20250034659A1 patent drawing

AI summary

This disclosure relates to assays and reagents for the detection of drug-resistance mutations in Mycobacterium. tuberculosis or of multidrug-resistant Mycobacterium tuberculosis.